Cisplatin nephrotoxicity: molecular mechanisms.

Cisplatin is one of the most widely used chemotherapeutic agents for the treatment of several human malignancies. The efficacy of cisplatin is dose dependent, but the significant risk of nephrotoxicity frequently hinders the use of higher doses to maximize its antineoplastic effects. Several advances in our understanding of the biochemical and molecular mechanisms underlying cisplatin nephrotoxicity have recently emerged, and are reviewed in this article. Evidence is presented for distinct mechanisms of cisplatin toxicity in actively dividing tumor cells versus the normally quiescent renal proximal tubular epithelial cells. The unexpected role of gamma-glutamyl transpeptidase in cisplatin nephrotoxicity is elucidated. Recent studies demonstrating the ability of proximal tubular cells to metabolize cisplatin to a nephrotoxin are reviewed. The evidence for apoptosis as a major mechanism underlying cisplatin-induced renal cell injury is presented, along with the data exploring the role of specific intracellular pathways that may mediate the programmed cell death. The information gleaned from this review may provide critical clues to novel therapeutic interventions aimed at minimizing cisplatin-induced nephrotoxicity while enhancing its antineoplastic efficacy.

[1]  W. Zeller,et al.  Positive correlation between cellular glutathione and acquired cisplatin resistance in human ovarian cancer cells , 1995, Cell Biology and Toxicology.

[2]  L. Rybak,et al.  Protection by ebselen against cisplatin-induced nephrotoxicity: Antioxidant system , 2004, Molecular and Cellular Biochemistry.

[3]  P. Mistry,et al.  Intracellular metabolites of cisplatin in the rat kidney , 2004, Cancer Chemotherapy and Pharmacology.

[4]  R. Mayer,et al.  Inhibition of cisplatin-induced nephrotoxicity in rats by buthionine sulfoximine, a glutathione synthesis inhibitor , 2004, Cancer Chemotherapy and Pharmacology.

[5]  Y. Iwamoto,et al.  Sodium thiosulfate inhibits cis-diamminedichloroplatinum (II) activity , 2004, Cancer Chemotherapy and Pharmacology.

[6]  J. Marto,et al.  High pressure liquid chromatography and mass spectrometry characterization of the nephrotoxic biotransformation products of Cisplatin. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[7]  T. Sugiyama,et al.  Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a chemoresistance marker in human oral squamous cell carcinoma treated with cisplatin. , 2003, Oral oncology.

[8]  T. Ninomiya,et al.  Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death. , 2003, Kidney international.

[9]  D. Townsend,et al.  Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells. , 2003, Journal of the American Society of Nephrology : JASN.

[10]  W. Curran New Chemotherapeutic Agents: Update of Major Chemoradiation Trials in Solid Tumors , 2002, Oncology.

[11]  Myriam Rochdi,et al.  Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. , 2002, Cancer research.

[12]  G. Nowak Protein Kinase C- (cid:1) and ERK1/2 Mediate Mitochondrial Dysfunction, Decreases in Active Na (cid:2) Transport, and Cisplatin-induced Apoptosis in Renal Cells* , 2022 .

[13]  S. Howell,et al.  The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. , 2002, Molecular pharmacology.

[14]  I. Herskowitz,et al.  Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[15]  G. Ramesh,et al.  TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity , 2002 .

[16]  K. Utsumi,et al.  L-Carnitine inhibits cisplatin-induced injury of the kidney and small intestine. , 2002, Archives of biochemistry and biophysics.

[17]  Arthur J. L. Cooper,et al.  Toxic, halogenated cysteine S-conjugates and targeting of mitochondrial enzymes of energy metabolism. , 2002, Biochemical pharmacology.

[18]  R. Schnellmann,et al.  Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. , 2002, The Journal of pharmacology and experimental therapeutics.

[19]  P. Devarajan,et al.  Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways. , 2002, Journal of the American Society of Nephrology : JASN.

[20]  Jerry Goodisman,et al.  Kinetics of cisplatin binding to cellular DNA and modulations by thiol-blocking agents and thiol drugs. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[21]  D. Townsend,et al.  Inhibition of gamma-glutamyl transpeptidase or cysteine S-conjugate beta-lyase activity blocks the nephrotoxicity of cisplatin in mice. , 2002, The Journal of pharmacology and experimental therapeutics.

[22]  R. H. Lee,et al.  Cisplatin-induced apoptosis by translocation of endogenous Bax in mouse collecting duct cells. , 2001, Biochemical pharmacology.

[23]  D. Townsend,et al.  (cid:2) -Glutamyl Transpeptidase-Deficient Mice Are Resistant to the Nephrotoxic Effects of Cisplatin , 2001 .

[24]  M. Fukumoto,et al.  Expression and cisplatin sensitivity of copper-transporting P-type adenosine triphosphatase (ATP7B) in human solid carcinoma cell lines. , 2001, Oncology reports.

[25]  Sudhir V. Shah,et al.  Role and regulation of activation of caspases in cisplatin-induced injury to renal tubular epithelial cells. , 2001, Kidney international.

[26]  W. Dekant Chemical-induced nephrotoxicity mediated by glutathione S-conjugate formation. , 2001, Toxicology letters.

[27]  R E Stoll,et al.  Assessment of cisplatin-induced nephrotoxicity by microarray technology. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.

[28]  B. van de Water,et al.  Suppression of Chemically Induced Apoptosis but Not Necrosis of Renal Proximal Tubular Epithelial (LLC-PK1) Cells by Focal Adhesion Kinase (FAK) , 2001, The Journal of Biological Chemistry.

[29]  A. Hishida,et al.  Role of the increase in p21 in cisplatin-induced acute renal failure in rats. , 2001, Journal of the American Society of Nephrology : JASN.

[30]  M. Inoue,et al.  Targeting superoxide dismutase to renal proximal tubule cells inhibits mitochondrial injury and renal dysfunction inuduced by cisplatin. , 2001, Archives of biochemistry and biophysics.

[31]  J. Stevens,et al.  Role of mitochondrial dysfunction in S-(1,2-dichlorovinyl)-l-cysteine-induced apoptosis. , 2001, Toxicology and applied pharmacology.

[32]  A. Langerak Chemotherapy Regimens and Cancer Care , 2001 .

[33]  Seth M. Cohen,et al.  Cisplatin: from DNA damage to cancer chemotherapy. , 2001, Progress in nucleic acid research and molecular biology.

[34]  S. Korsmeyer,et al.  Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c , 2000, Cell Death and Differentiation.

[35]  G. Kroemer,et al.  Mitochondria--the Death Signal Integrators , 2000, Science.

[36]  B. van de Water,et al.  Cleavage of the Actin-capping Protein α-Adducin at Asp-Asp-Ser-Asp633-Ala by Caspase-3 Is Preceded by Its Phosphorylation on Serine 726 in Cisplatin-induced Apoptosis of Renal Epithelial Cells* , 2000, The Journal of Biological Chemistry.

[37]  M. Kool,et al.  A family of drug transporters: the multidrug resistance-associated proteins. , 2000, Journal of the National Cancer Institute.

[38]  M. V. Heiden,et al.  Redox regulation of p53 during hypoxia , 2000, Oncogene.

[39]  M. Mariggiò,et al.  Reduction of cisplatin nephrotoxicity by procainamide: does the formation of a cisplatin-procainamide complex play a role? , 2000, The Journal of pharmacology and experimental therapeutics.

[40]  L. Truong,et al.  Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis. , 2000, American journal of physiology. Renal physiology.

[41]  G. Kaushal,et al.  Apoptotic mechanisms in acute renal failure. , 2000, The American journal of medicine.

[42]  A. Hishida,et al.  Role of apoptosis in uranyl acetate-induced acute renal failure and acquired resistance to uranyl acetate. , 2000, Kidney international.

[43]  N. Farrell,et al.  Platinum-Based Drugs in Cancer Therapy , 2000, Cancer Drug Discovery and Development.

[44]  Gerard I. Evan,et al.  The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant , 2000, Nature Cell Biology.

[45]  M. Mutoh,et al.  Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. , 2000, Cancer research.

[46]  M. Okuda,et al.  Role of apoptosis in cisplatin-induced toxicity in the renal epithelial cell line LLC-PK1. Implication of the functions of apical membranes. , 2000, Biochemical pharmacology.

[47]  S. Howell,et al.  How Does Cisplatin Kill Cells , 2000 .

[48]  M. McKeage Clinical Toxicology of Platinum-Based Cancer Chemotherapeutic Agents , 2000 .

[49]  F. Hamada,et al.  Prevention of cisplatin-induced nephrotoxicity by methimazole. , 2000, Pharmacological research.

[50]  A. Hishida,et al.  Attenuation of cisplatin-induced acute renal failure is associated with less apoptotic cell death. , 1999, The Journal of laboratory and clinical medicine.

[51]  J. Stevens,et al.  The roles of caspase-3 and bcl-2 in chemically-induced apoptosis but not necrosis of renal epithelial cells , 1999, Oncogene.

[52]  T. Burns,et al.  The p53 pathway and apoptosis , 1999, Journal of cellular physiology.

[53]  S. Fulda,et al.  Cytotoxic drugs and the CD95 pathway , 1999, Leukemia.

[54]  A. Lau,et al.  Apoptosis induced by cisplatin nephrotoxic injury. , 1999, Kidney international.

[55]  M W Parker,et al.  The ligandin (non-substrate) binding site of human Pi class glutathione transferase is located in the electrophile binding site (H-site). , 1999, Journal of molecular biology.

[56]  M. del Río,et al.  Partial ATP depletion induces Fas- and caspase-mediated apoptosis in MDCK cells. , 1999, American journal of physiology. Renal physiology.

[57]  M. Razzaque,et al.  Cisplatin-induced apoptosis in human proximal tubular epithelial cells is associated with the activation of the Fas/Fas ligand system , 1999, Histochemistry and Cell Biology.

[58]  Y. Sugiyama,et al.  Differences in Substrate Specificity among Glutathione Conjugates (GS‐X) Pump Family Members: Comparison between Multidrug Resistance‐associated Protein and a Novel Transporter Expressed on a Cisplatin‐resistant Cell Line (KCP‐4) , 1999, Japanese journal of cancer research : Gann.

[59]  D. Townsend,et al.  Gamma-glutamyl transpeptidase accelerates tumor growth and increases the resistance of tumors to cisplatin in vivo. , 1999, Carcinogenesis.

[60]  A. Lichtenstein,et al.  Differential effects of cisplatin in proximal and distal renal tubule epithelial cell lines , 1999, British Journal of Cancer.

[61]  利仁 福岡 Distinct Interleukin-1 β-Converting Enzyme Family Proteases Mediate Cisplatin- and Staurosporine-induced Apoptosis of Mouse Proximal Tubule Cells , 1998 .

[62]  J. Weinberg,et al.  Mechanisms of cell death in hypoxia/reoxygenation injury , 1998, Oncogene.

[63]  D. Israeli,et al.  p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs , 1998, The Journal of experimental medicine.

[64]  Masahiro Higuchi,et al.  Regulation of reactive oxygen species-induced apoptosis and necrosis by caspase 3-like proteases , 1998, Oncogene.

[65]  J. Lindsay,et al.  Mitochondrial stress protein recognition of inactivated dehydrogenases during mammalian cell death. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[66]  R. Perez,et al.  Cellular and molecular determinants of cisplatin resistance. , 1998, European journal of cancer.

[67]  V. Dixit,et al.  Death receptors: signaling and modulation. , 1998, Science.

[68]  S. Cory,et al.  The Bcl-2 protein family: arbiters of cell survival. , 1998, Science.

[69]  Y. Lazebnik,et al.  Caspases: enemies within. , 1998, Science.

[70]  Xiaodong Wang,et al.  Bid, a Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death Receptors , 1998, Cell.

[71]  G. Mulder,et al.  Cisplatin effects on F-actin and matrix proteins precede renal tubular cell detachment and apoptosis in vitro , 1998, Cell Death and Differentiation.

[72]  A. Hishida,et al.  The role of oxygen free radicals in cisplatin-induced acute renal failure in rats. , 1998, The Journal of laboratory and clinical medicine.

[73]  L. Dworkin,et al.  Hepatocyte growth factor protects renal epithelial cells from apoptotic cell death. , 1998, Biochemical and biophysical research communications.

[74]  B. Trock,et al.  Association between expression of glutathione-associated enzymes and response to platinum-based chemotherapy in head and neck cancer. , 1998, Chemico-biological interactions.

[75]  K. Schulze-Osthoff,et al.  Role of Reactive Oxygen Intermediates in Activation-induced CD95 (APO-1/Fas) Ligand Expression* , 1998, The Journal of Biological Chemistry.

[76]  Y. Nakanishi,et al.  Induction of apoptosis in ischemia-reperfusion model of mouse kidney: possible involvement of Fas. , 1998, Journal of the American Society of Nephrology : JASN.

[77]  S. Wright,et al.  Na-dependent transport of S-(1,2-dichlorovinyl)-L-cysteine by renal brush-border membrane vesicles. , 1998, The Journal of pharmacology and experimental therapeutics.

[78]  J. Megyesi,et al.  Induction of p21WAF1/CIP1/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure. , 1998, The Journal of clinical investigation.

[79]  Y. Minagawa,et al.  Glutathione concentration may be a useful predictor of response to second‐line chemotherapy in patients with ovarian cancer , 1998, Cancer.

[80]  X. Chen,et al.  [The expression of glutathione S-transferase pi in human ovarian cancer as an indicator of resistance to chemotherapy]. , 1998, Zhonghua fu chan ke za zhi.

[81]  W. van der Vijgh,et al.  Pharmacokinetics of cisplatin with and without amifostine in tumour-bearing nude mice. , 1998, European journal of cancer.

[82]  H. Endou,et al.  Involvement of macromolecule synthesis, endonuclease activation and c-fos expression in cisplatin-induced apoptosis of mouse proximal tubule cells. , 1998, Toxicology letters.

[83]  W. Dekant,et al.  Glutathione-dependent bioactivation of haloalkenes. , 1998, Annual review of pharmacology and toxicology.

[84]  D. Putt,et al.  Glutathione conjugation of trichloroethylene in rats and mice: sex-, species-, and tissue-dependent differences. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[85]  K. Kinzler,et al.  14-3-3σ Is a p53-Regulated Inhibitor of G2/M Progression , 1997 .

[86]  John Calvin Reed,et al.  Cytochrome c: Can't Live with It—Can't Live without It , 1997, Cell.

[87]  A. V. D. Van Der Zee,et al.  hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents , 1997, Oncogene.

[88]  R. Prescott,et al.  Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[89]  Sudhir V. Shah,et al.  Oxidant mechanisms in toxic acute renal failure. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[90]  Y. Minagawa,et al.  Glutathione S‐transferase‐π expression and glutathione concentration in ovarian carcinoma before and after chemotherapy , 1997 .

[91]  B. van de Water,et al.  Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. , 1997, The Journal of pharmacology and experimental therapeutics.

[92]  H. Endou,et al.  Cisplatin-induced apoptosis of immortalized mouse proximal tubule cells is mediated by interleukin-1β converting enzyme (ICE) family of proteases but inhibited by overexpression of Bcl-2 , 1997, Archives of Toxicology.

[93]  J. Megyesi,et al.  The p53-independent activation of transcription of p21 WAF1/CIP1/SDI1 after acute renal failure. , 1996, The American journal of physiology.

[94]  H. Frierson,et al.  Immunohistochemical detection of gamma-glutamyl transpeptidase in normal human tissue. , 1996, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[95]  M. Esposito,et al.  Effect of the antiarrhythmic drug procainamide on the toxicity and antitumor activity of cis-diamminedichloroplatinum(II). , 1996, Toxicology and applied pharmacology.

[96]  T. Takayama,et al.  Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide. , 1996, Cancer research.

[97]  T. Ishikawa,et al.  Coordinated Induction of MRP/GS-X Pump and γ-Glutamylcysteine Synthetase by Heavy Metals in Human Leukemia Cells* , 1996, The Journal of Biological Chemistry.

[98]  W. Lieberthal,et al.  Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. , 1996, The American journal of physiology.

[99]  J. Brisson,et al.  Markers of chemoresistance in ovarian carcinomas: an immunohistochemical study of 86 cases. , 1996, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[100]  J. Morin,et al.  The cellular toxicity of two antitumoural agents derived from platinum, cisplatinum versus oxaliplatinum, on cultures of tubular proximal cells. , 1996, Drugs under experimental and clinical research.

[101]  J. Megyesi,et al.  DNA synthesis is dissociated from the immediate-early gene response in the post-ischemic kidney. , 1995, Kidney international.

[102]  S. Lippard,et al.  Cisplatin and DNA repair in cancer chemotherapy. , 1995, Trends in biochemical sciences.

[103]  R. Schlapbach,et al.  Oxidants in mitochondria: from physiology to diseases. , 1995, Biochimica et biophysica acta.

[104]  M. W. Anders Mitochondrial bioactivation of cysteine S-conjugates and 4-thiaalkanoates: implications for mitochondrial dysfunction and mitochondrial diseases. , 1995, Biochimica et biophysica acta.

[105]  P. Teesdale-Spittle,et al.  The C-S lysis of L-cysteine conjugates by aspartate and alanine aminotransferase enzymes , 1995, Human & experimental toxicology.

[106]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.

[107]  H. Furumoto,et al.  Expression of glutathione S‐transferase‐π in human ovarian cancer as an indicator of resistance to chemotherapy , 1994 .

[108]  P. Taylor,et al.  Inhibition of gamma-glutamyl transpeptidase activity by acivicin in vivo protects the kidney from cisplatin-induced toxicity. , 1994, Cancer research.

[109]  Inhibition of cisplatin toxicity without decreasing antitumor efficacy. Use of a dithiocarbamate. , 1994, Archives of otolaryngology--head & neck surgery.

[110]  Z. Oltvai,et al.  Checkpoints of dueling dimers foil death wishes , 1994, Cell.

[111]  Sadzuka Yasuyuki,et al.  Protection against cisplatin-induced nephrotoxicity in the rat by inducers and an inhibitor of glutathione S-transferase. , 1994 .

[112]  K. Matsumoto,et al.  Hepatocyte growth factor prevents acute renal failure and accelerates renal regeneration in mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[113]  A. Cooley,et al.  Roles of cysteine conjugate beta-lyase and S-oxidase in nephrotoxicity: studies with S-(1,2-dichlorovinyl)-L-cysteine and S-(1,2-dichlorovinyl)-L-cysteine sulfoxide. , 1994, The Journal of pharmacology and experimental therapeutics.

[114]  Y. Sadzuka,et al.  Role of glutathione S-transferase isoenzymes in cisplatin-induced nephrotoxicity in the rat. , 1994, Toxicology letters.

[115]  S. Hirota,et al.  Protection against cisplatin-induced nephrotoxicity in the rat by inducers and an inhibitor of glutathione S-transferase. , 1994, Biochemical pharmacology.

[116]  Gilbert Chu,et al.  Massive cisplatin overdose by accidental substitution for carboplatin. Toxicity and management , 1993, Cancer.

[117]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[118]  J. Stevens,et al.  Mitochondrial HSP60 (P1 protein) and a HSP70-like protein (mortalin) are major targets for modification during S-(1,1,2,2-tetrafluoroethyl)-L-cysteine-induced nephrotoxicity. , 1993, The Journal of biological chemistry.

[119]  T. Cornelison,et al.  Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. , 1993, Gynecologic oncology.

[120]  W. Ricketts,et al.  Extracellular glutathione is a source of cysteine for cells that express gamma-glutamyl transpeptidase. , 1993, Biochemistry.

[121]  S. Gullans,et al.  Differential actions of cisplatin on renal proximal tubule and inner medullary collecting duct cells. , 1993, The Journal of pharmacology and experimental therapeutics.

[122]  S. Howell,et al.  Cellular accumulation of the anticancer agent cisplatin: a review. , 1993, British Journal of Cancer.

[123]  A. McGown,et al.  The role of metallothionein, glutathione, glutathione S-transferases and DNA repair in resistance to platinum drugs in a series of L1210 cell lines made resistant to anticancer platinum agents. , 1993, Biochemical pharmacology.

[124]  D. Crowther,et al.  Glutathione S-transferase activity and isoenzyme distribution in ovarian tumour biopsies taken before or after cytotoxic chemotherapy. , 1992, British journal of cancer.

[125]  H. Hollema,et al.  Glutathione S-transferase activity and isoenzyme composition in benign ovarian tumours, untreated malignant ovarian tumours, and malignant ovarian tumours after platinum/cyclophosphamide chemotherapy. , 1992, British Journal of Cancer.

[126]  Y. Sadzuka,et al.  Effect of cisplatin on the activities of enzymes which protect against lipid peroxidation. , 1992, Biochemical pharmacology.

[127]  M. Raff,et al.  Social controls on cell survival and cell death , 1992, Nature.

[128]  A. Godwin,et al.  High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[129]  M. Jones,et al.  Control of the nephrotoxicity of cisplatin by clinically used sulfur-containing compounds. , 1992, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[130]  K. Cowan,et al.  Expression of human mu or alpha class glutathione S-transferases in stably transfected human MCF-7 breast cancer cells: effect on cellular sensitivity to cytotoxic agents. , 1992, Molecular pharmacology.

[131]  F. Zunino,et al.  The role of glutathione in combination with cisplatin in the treatment of ovarian cancer. , 1991, Cancer treatment reviews.

[132]  J. Stevens,et al.  Detection of cysteine conjugate metabolite adduct formation with specific mitochondrial proteins using antibodies raised against halothane metabolite adducts. , 1991, The Journal of biological chemistry.

[133]  N. Vermeulen,et al.  Metabolism of L-cysteine S-conjugates and N-(trideuteroacetyl)-L-cysteine S-conjugates of four fluoroethylenes in the rat. Role of balance of deacetylation and acetylation in relation to the nephrotoxicity of mercapturic acids. , 1991, Biochemical pharmacology.

[134]  B. Leyland-Jones,et al.  Antineoplastic drug sensitivity of human MCF-7 breast cancer cells stably transfected with a human alpha class glutathione S-transferase gene. , 1991, Cancer research.

[135]  N. Fukuishi,et al.  Amelioration by ascorbic acid of cisplatin-induced injury in cultured renal epithelial cells. , 1991, Contributions to nephrology.

[136]  S. Gullans,et al.  Mitochondrial injury: an early event in cisplatin toxicity to renal proximal tubules. , 1990, The American journal of physiology.

[137]  P. Kuchel,et al.  Reaction of cis- and trans-[PtCl2(NH3)2] with reduced glutathione studied by 1H, 13C, 195Pt and 15N-{1H} DEPT NMR , 1990 .

[138]  R. Puchalski,et al.  Expression of recombinant glutathione S-transferase pi, Ya, or Yb1 confers resistance to alkylating agents. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[139]  P. Kuchel,et al.  Reaction of cis- and trans-[PtCl2(NH3)2] with reduced glutathione inside human red blood cells, studied by 1H and 15N-[1H] DEPT NMR. , 1990, Journal of inorganic biochemistry.

[140]  J. Yokota,et al.  Glutathione-S-transferase pi as a determinant of drug resistance in transfectant cell lines. , 1990, The Journal of biological chemistry.

[141]  J. Stevens,et al.  Cysteine conjugate toxicity, metabolism, and binding to macromolecules in isolated rat kidney mitochondria. , 1990, Molecular pharmacology.

[142]  G. Singh A possible cellular mechanism of cisplatin-induced nephrotoxicity. , 1989, Toxicology.

[143]  T. Montine,et al.  Quiescent LLC-PK1 cells as a model for cis-diamminedichloroplatinum(II) nephrotoxicity and modulation by thiol rescue agents. , 1988, Cancer research.

[144]  D. J. Reed,et al.  Nephrotoxicity of S-(2-chloroethyl)glutathione in the Fischer rat: evidence for gamma-glutamyltranspeptidase-independent uptake by the kidney. , 1987, The Journal of pharmacology and experimental therapeutics.

[145]  Z. Siddik,et al.  The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. , 1987, Biochemical pharmacology.

[146]  V. Gattone,et al.  Mitochondrial alterations in cisplatin-induced acute renal failure. , 1986, The American journal of physiology.

[147]  L. Lash,et al.  Renal cysteine conjugate beta-lyase. Bioactivation of nephrotoxic cysteine S-conjugates in mitochondrial outer membrane. , 1986, The Journal of biological chemistry.

[148]  L. Lash,et al.  Metabolic activation and detoxication of nephrotoxic cysteine and homocysteine S-conjugates. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[149]  H. Pitot,et al.  Gamma-glutamyl transpeptidase--its role in hepatocarcinogenesis. , 1985, Carcinogenesis.

[150]  P. Daley-Yates,et al.  Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumour activity of cisplatin. , 1984, Biochemical pharmacology.

[151]  A. J. Gandolfi,et al.  The formation and biotransformation of cysteine conjugates of halogenated ethylenes by rabbit renal tubules. , 1984, Chemico-biological interactions.

[152]  E. Lock,et al.  The metabolism and disposition of hexachloro-1:3-butadiene in the rat and its relevance to nephrotoxicity. , 1984, Toxicology and applied pharmacology.

[153]  E. Lock,et al.  Role of microsomal and cytosolic glutathione S-transferases in the conjugation of hexachloro-1:3-butadiene and its possible relevance to toxicity. , 1984, The Journal of pharmacology and experimental therapeutics.

[154]  P. Bénard,et al.  Whole-body autoradiographic study of the distribution of 195mPt in healthy and tumor-bearing mice treated with labeled cisplatin. , 1983, Cancer treatment reports.

[155]  N. Curthoys,et al.  Renal catabolism of glutathione. Characterization of a particulate rat renal dipeptidase that catalyzes the hydrolysis of cysteinylglycine. , 1982, The Journal of biological chemistry.

[156]  R. Borch,et al.  Effect of diethyldithiocarbamate rescue on tumor response to cis-platinum in a rat model. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[157]  S. Howell,et al.  Effect of sodium thiosulfate on cis-dichlorodiammineplatinum(II) toxicity and antitumor activity in L1210 leukemia. , 1980, Cancer treatment reports.

[158]  N. Curthoys,et al.  Characterization and physiological function of rat renal gamma-glutamyltranspeptidase. , 1979, Enzyme.

[159]  N. Curthoys,et al.  Specificity of a particulate rat renal peptidase and its localization along with other enzymes of mercapturic acid synthesis. , 1978, Archives of biochemistry and biophysics.

[160]  J. Hokanson,et al.  Amelioration of cis-platinum nephrotoxicity by orgotein (superoxide dismutase). , 1978, Physiological chemistry and physics.

[161]  S. Sternberg,et al.  The renal pathology in clinical trials of Cis‐platinum (II) diamminedichloride , 1977, Cancer.

[162]  R. Lange,et al.  Clinical and pharmacological studies with cis-diamminedichloroplatinum (II). , 1973, Cancer research.

[163]  R. P. Spencer,et al.  The antitumor agent cis-Pt(NH 3 ) 2 Cl 2 : distribution studies and dose calculations for 193m Pt and 195m Pt. , 1973, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[164]  A. Wyllie,et al.  Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.

[165]  A. S. Appel,et al.  Acute Renal Failure , 1960, Advances in Experimental Medicine and Biology.